Next Article in Journal
The Relationship of Eating Rate and Degree of Chewing to Body Weight Status among Preschool Children in Japan: A Nationwide Cross-Sectional Study
Next Article in Special Issue
Beneficial Effects of Vitamin D Treatment in an Obese Mouse Model of Non-Alcoholic Steatohepatitis
Previous Article in Journal
Dietary Patterns and Their Sociodemographic and Lifestyle Determinants in Switzerland: Results from the National Nutrition Survey menuCH
Previous Article in Special Issue
Protective Role of Polyphenols against Vascular Inflammation, Aging and Cardiovascular Disease
Open AccessFeature PaperArticle

Tart Cherry Prevents Bone Loss through Inhibition of RANKL in TNF-Overexpressing Mice

1
Department of Medicine, Case Western Reserve University, Cleveland, OH 44104, USA
2
Department of Orthopaedic Surgery, Columbia University, New York, NY 10032, USA
3
The Institutes of Food, CJ CheilJedang, CJ Blossom Park, 42, Gwanggyo-ro, Yeondong-gu, Suwon-si, Gyeonggi-do 16495, Korea
*
Author to whom correspondence should be addressed.
Nutrients 2019, 11(1), 63; https://doi.org/10.3390/nu11010063
Received: 18 November 2018 / Revised: 23 December 2018 / Accepted: 24 December 2018 / Published: 29 December 2018
(This article belongs to the Special Issue Inflammation- An Ancient Battle. What are the Roles of Nutrients?)
Current drugs for the treatment of rheumatoid arthritis-associated bone loss come with concerns about their continued use. Thus, it is necessary to identify natural products with similar effects, but with fewer or no side effects. We determined whether tart cherry (TC) could be used as a supplement to prevent inflammation-mediated bone loss in tumor necrosis factor (TNF)-overexpressing transgenic (TG) mice. TG mice were assigned to a 0%, 5%, or 10% TC diet, with a group receiving infliximab as a positive control. Age-matched wild-type (WT) littermates fed a 0% TC diet were used as a normal control. Mice were monitored by measurement of body weight. Bone health was evaluated via serum biomarkers, microcomputed tomography (µCT), molecular assessments, and mechanical testing. TC prevented TNF-mediated weight loss, while it did not suppress elevated levels of interleukin (IL)-1β and IL-6. TC also protected bone structure from inflammation-induced bone loss with a reduced ratio of receptor activator of nuclear factor kappa-B ligand (RANKL)/osteoprotegerin (OPG) to a degree comparable to infliximab. Furthermore, unlike with infliximab, TC exhibited a moderate improvement in TNF-mediated decline in bone stiffness. Thus, TC could be used as a prophylactic regimen against future fragility fractures in the context of highly chronic inflammation. View Full-Text
Keywords: tart cherry; rheumatoid arthritis; TNF; osteoblast; osteoclast; RANKL; OPG; Runx2; bone mass; infliximab tart cherry; rheumatoid arthritis; TNF; osteoblast; osteoclast; RANKL; OPG; Runx2; bone mass; infliximab
Show Figures

Figure 1

MDPI and ACS Style

Moon, N.; Effiong, L.; Song, L.; Gardner, T.R.; Soung, D.Y. Tart Cherry Prevents Bone Loss through Inhibition of RANKL in TNF-Overexpressing Mice. Nutrients 2019, 11, 63.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop